

Pharmacokinetic profile of orally administered itraconazole

Journal of the American Academy of Dermatology
18, 263-268

DOI: [10.1016/s0190-9622\(88\)70037-7](https://doi.org/10.1016/s0190-9622(88)70037-7)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Role of Animal and Human Pharmacology in Antifungal Drug Design. <i>Annals of the New York Academy of Sciences</i> , 1988, 544, 264-269.	1.8	12
2	The Clinical Pharmacokinetics of Itraconazole: An Overview. <i>Mycoses</i> , 1989, 32, 67-87.	1.8	343
3	Double-Blind Comparison of Itraconazole with Griseofulvin in the Treatment of Tinea Corporis and Tinea Cruris. <i>International Journal of Dermatology</i> , 1989, 28, 410-412.	0.5	51
4	Itraconazole. <i>Drugs</i> , 1989, 37, 310-344.	4.9	381
5	Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 1990, 34, 448-454.	1.4	25
6	Cutaneous Leishmaniasis In India.. <i>International Journal of Dermatology</i> , 1990, 29, 661-662.	0.5	65
7	How orally administered terbinafine reaches the stratum corneum. <i>Journal of Dermatological Treatment</i> , 1990, 1, 23-25.	1.1	36
8	Antifungal drugs-an introduction. <i>Journal of Dermatological Treatment</i> , 1990, 1, 1-3.	1.1	15
9	Problems of resistant dermatophytes. <i>Journal of the American Academy of Dermatology</i> , 1990, 23, 779-781.	0.6	18
10	Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. <i>Journal of the American Academy of Dermatology</i> , 1990, 22, 211-215.	0.6	19
11	Itraconazole in common dermatophyte infections of the skin: Fixed treatment schedules. <i>Journal of the American Academy of Dermatology</i> , 1990, 23, 554-558.	0.6	31
12	Fluconazole. <i>Drugs</i> , 1990, 39, 877-916.	4.9	497
13	Treatment of chromoblastomycosis. <i>Journal of the American Academy of Dermatology</i> , 1990, 23, 728-732.	0.6	37
14	Itraconazole in the treatment of superficial mycoses-a double-blind study vs. placebo. <i>Clinical and Experimental Dermatology</i> , 1990, 15, 101-104.	0.6	37
15	Treatment of onychomycosis with itraconazole. <i>Journal of Dermatological Treatment</i> , 1992, 2, 145-146.	1.1	19
16	Pharmacokinetics of terbinafine in the nail. <i>Journal of Dermatological Treatment</i> , 1992, 3, 15-17.	1.1	11
17	Itraconazole in Antifungal Therapy. <i>Annals of Pharmacotherapy</i> , 1992, 26, 502-509.	0.9	61
18	Itraconazole versus griseofulvin. A double-blind comparison in patients with tinea corporis and tinea cruris. <i>Journal of Dermatological Treatment</i> , 1992, 3, 23-25.	1.1	5

#	ARTICLE	IF	CITATIONS
19	A Comparison of Itraconazole and Griseofulvin in the Treatment of Tinea Corporis and Tinea Cruris: A Double-Blind Study. <i>Journal of International Medical Research</i> , 1992, 20, 392-400.	0.4	17
20	Posttreatment itraconazole levels in the nail. <i>Journal of the American Academy of Dermatology</i> , 1992, 26, 731-735.	0.6	163
21	New therapeutic concepts in onychomycosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 1992, 1, S21-S24.	1.3	4
22	Pharmacokinetics of terbinafine in the nail. <i>British Journal of Dermatology</i> , 1992, 126, 28-32.	1.4	78
23	Levels of fluconazole in serum, stratum corneum, epidermis-dermis (without stratum corneum) and eccrine sweat. <i>Clinical and Experimental Dermatology</i> , 1993, 18, 102-106.	0.6	87
24	Itraconazole in the treatment of tinea corporis and tinea cruris. <i>Clinical and Experimental Dermatology</i> , 1993, 18, 322-325.	0.6	16
25	Folliculitis in Down's syndrome. <i>British Journal of Dermatology</i> , 1993, 129, 696-699.	1.4	27
26	SYSTEMIC DRUGS IN THE TREATMENT OF DERMATOPHYTOSES. <i>International Journal of Dermatology</i> , 1993, 32, 16-21.	0.5	24
27	Pharmacokinetic Optimisation of Oral Antifungal Therapy. <i>Clinical Pharmacokinetics</i> , 1993, 25, 329-341.	1.6	67
28	Kinetics and spectrum of activity of oral antifungals: The therapeutic implications. <i>Journal of the American Academy of Dermatology</i> , 1993, 29, S37-S41.	0.6	34
29	Cutaneous Alternariosis in a Liver Transplant Recipient. <i>Clinical Infectious Diseases</i> , 1993, 16, 729-730.	2.9	26
30	Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 1993, 37, 2064-2068.	1.4	63
31	Acute Pancreatitis Associated with the Administration of Meglumine Antimonate for the Treatment of Visceral Leishmaniasis. <i>Clinical Infectious Diseases</i> , 1993, 16, 730-731.	2.9	21
32	Candidiasis Endocrinopathy Syndrome. <i>Archives of Dermatology</i> , 1994, 130, 19.	1.7	14
33	Itraconazole: A New Triazole Antifungal Agent. <i>Infection Control and Hospital Epidemiology</i> , 1994, 15, 397-410.	1.0	30
34	ITRACONAZOLE VERSUS GRISEOFULVIN IN THE TREATMENT OF TINEA CAPITIS: A DOUBLE-BLIND RANDOMIZED STUDY IN CHILDREN. <i>International Journal of Dermatology</i> , 1994, 33, 743-747.	0.5	130
35	Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days. <i>Clinical and Experimental Dermatology</i> , 1994, 19, 121-126.	0.6	113
36	Antifungal agents: An overview. Part II. <i>Journal of the American Academy of Dermatology</i> , 1994, 30, 911-933.	0.6	252

#	ARTICLE	IF	CITATIONS
37	Oral Azole Drugs as Systemic Antifungal Therapy. <i>New England Journal of Medicine</i> , 1994, 330, 263-272.	13.9	565
38	Leishmaniasis and itraconazole: a controlled clinical trial on cutaneous subtypes. <i>International Journal of Antimicrobial Agents</i> , 1994, 4, 309-311.	1.1	6
39	Current therapy of dermatophytosis. <i>Journal of the American Academy of Dermatology</i> , 1994, 31, S25-S30.	0.6	68
40	Double-blind comparison of itraconazole and placebo in the treatment of tinea corporis and tinea cruris. <i>Journal of the American Academy of Dermatology</i> , 1994, 31, 232-234.	0.6	15
41	A Case of Deep Cutaneous Candidiasis.. <i>Medical Mycology Journal</i> , 1995, 36, 175-178.	0.9	0
42	Low Itraconazole Serum Concentrations Following Administration of Itraconazole Suspension to Critically Ill Allogeneic Bone Marrow Transplant Recipients. <i>Annals of Pharmacotherapy</i> , 1995, 29, 140-143.	0.9	21
43	Itraconazole in the Treatment of Sporotrichosis: A Korean Experience. <i>Tropical Doctor</i> , 1995, 25, 107-109.	0.2	3
44	TINEA PEDIS (MOCASSINTYPE) TREATED WITH ITRACONAZOLE. <i>International Journal of Dermatology</i> , 1995, 34, 122-124.	0.5	27
46	EVOLVING ROLE OF NONDERMATOPHYTES IN ONYCHOMYCOSIS. <i>International Journal of Dermatology</i> , 1995, 34, 521-524.	0.5	88
47	Feline Dermatophytosis: Recent Advances and Recommendations for Therapy. <i>Veterinary Clinics of North America - Small Animal Practice</i> , 1995, 25, 901-921.	0.5	39
48	Potential use of a simplified method for determination of itraconazole levels in plasma and esophageal tissue by using high-performance liquid chromatography. <i>Antimicrobial Agents and Chemotherapy</i> , 1995, 39, 757-759.	1.4	17
49	Antifungal activity of itraconazole and terbinafine in human stratum corneum: A comparative study. <i>Journal of the American Academy of Dermatology</i> , 1995, 32, 429-435.	0.6	50
50	Onychomycosis caused by <i>Microsporum canis</i> : Treatment with itraconazole. <i>Journal of the American Academy of Dermatology</i> , 1995, 32, 1052-1053.	0.6	13
51	Determination of Itraconazole and Hydroxy-itraconazole in sera using high-performance-liquid-chromatography and a bioassay. <i>Zentralblatt Fur Bakteriologie: International Journal of Medical Microbiology</i> , 1995, 282, 457-464.	0.5	6
52	Treatment and Prophylaxis of Tinea Infections. <i>Drugs</i> , 1996, 52, 209-224.	4.9	53
53	Itraconazole and leishmaniasis: A randomised double-blind trial in cutaneous disease. <i>International Journal for Parasitology</i> , 1996, 26, 1413-1415.	1.3	78
54	Itraconazole. <i>Drugs</i> , 1996, 51, 585-620.	4.9	147
55	Clinical and Economic Factors in the Treatment of Onychomycosis. <i>Pharmacoeconomics</i> , 1996, 9, 307-320.	1.7	21

#	ARTICLE	IF	CITATIONS
56	3. Tinea of the skin, hair and nails. Medical Journal of Australia, 1996, 164, 552-556.	0.8	4
57	Therapeutic Efficacy of TP-101 in a Guinea Pig Model of Dermatophytosis. Comparison of Drug Level in Stratum Corneum and Therapeutic Efficacy with 1% MCZ Cream.. Medical Mycology Journal, 1996, 37, 19-23.	0.9	0
58	DOUBLE-BLIND, RANDOMIZED COMPARISON OF ITRACONAZOLE CAPSULES AND PLACEBO IN ONYCHOMYCOSIS OF TOENAIL. International Journal of Dermatology, 1996, 35, 589-590.	0.5	31
59	Antifungal Pulse Therapy for Onychomycosis. Archives of Dermatology, 1996, 132, 34.	1.7	68
61	Update on Invasive Candidiasis. Advances in Pharmacology, 1996, 37, 349-400.	1.2	15
62	Pediatrics: Treatment of Tinea Capitis. Annals of Pharmacotherapy, 1997, 31, 338-348.	0.9	43
63	Oral Terbinafine: A New Antifungal Agent. Annals of Pharmacotherapy, 1997, 31, 445-456.	0.9	94
64	Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections. Clinical Infectious Diseases, 1997, 24, 235-247.	2.9	872
65	CURRENT MANAGEMENT OF ONYCHOMYCOSIS. Dermatologic Clinics, 1997, 15, 121-135.	1.0	71
66	Itraconazole pulse therapy for onychomycosis and dermatomycoses: An overview. Journal of the American Academy of Dermatology, 1997, 37, 969-974.	0.6	85
67	Pediatric dermatology: Advances in therapy. Journal of the American Academy of Dermatology, 1997, 36, 513-530.	0.6	13
68	Itraconazole for the treatment of tinea pedis: A dosage of 400 mg/day given for 1 week is similar in efficacy to 100 or 200 mg/day given for 2 to 4 weeks. Journal of the American Academy of Dermatology, 1997, 36, 789-792.	0.6	28
69	Small-dose itraconazole pulse therapy in the treatment of onychomycosis. Mycoses, 1997, 40, 397-400.	1.8	24
71	Oral itraconazole therapy for pityriasis versicolor. Journal of the European Academy of Dermatology and Venereology, 1997, 8, 203-207.	1.3	3
72	Microassay for determination of itraconazole and hydroxyitraconazole in plasma and tissue biopsies. Biomedical Applications, 1997, 702, 175-180.	1.7	23
73	Itraconazole pulse therapy is effective in the treatment of tinea capitis in children: an open multicentre study. British Journal of Dermatology, 1997, 137, 251-254.	1.4	58
74	A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. British Journal of Dermatology, 1997, 136, 230-234.	1.4	44
75	Efficacy of oral fluconazole in tinea pedis of the hyperkeratotic type. Stratum corneum levels. Mycoses, 1998, 41, 153-162.	1.8	17

#	ARTICLE	IF	CITATIONS
76	An intermittent itraconazole 1â€week dosing regimen for the treatment of toenail onychomycosis in dermatological practice. <i>Mycoses</i> , 1998, 41, 235-238.	1.8	33
77	Antimykotische Behandlung der Tinea capitis im Kindesalter mit Itraconazol. <i>Monatsschrift Fur Kinderheilkunde</i> , 1998, 146, 121-124.	0.1	0
79	Itraconazole for the treatment of onychomycosis. <i>International Journal of Dermatology</i> , 1998, 37, 303-308.	0.5	78
80	Kwashiorkor/zinc deficiency overlap following partial gastrectomy. <i>International Journal of Dermatology</i> , 1998, 37, 134-137.	0.5	12
81	Cutaneous bronchogenic cysts. <i>International Journal of Dermatology</i> , 1998, 37, 137-140.	0.5	21
82	Clobetasol propionate emollient 0.05% in the treatment of atopic dermatitis. <i>International Journal of Dermatology</i> , 1998, 37, 142-144.	0.5	28
83	Flexural purpura and Epsteinâ€Barr virus infection. <i>International Journal of Dermatology</i> , 1998, 37, 130-132.	0.5	3
85	Shortâ€term itraconazole versus terbinafine in the treatment of tinea pedis or manus. <i>International Journal of Dermatology</i> , 1998, 37, 140-142.	0.5	29
86	Wellâ€differentiated squamous cell carcinoma of the penis associated with HPV type 33. <i>International Journal of Dermatology</i> , 1998, 37, 128-130.	0.5	17
87	Anhidrotic ectodermal dysplasia (Christâ€Siemensâ€Touraine syndrome) presenting as a fever of unknown origin in an infant. <i>International Journal of Dermatology</i> , 1998, 37, 132-134.	0.5	10
88	Tinea versicolor. <i>International Journal of Dermatology</i> , 1998, 37, 648-655.	0.5	47
89	Itraconazole pulse therapy is effective in the treatment of Majocchi's granuloma: a clinical and pharmacokinetic evaluation and implications for possible effectiveness in tinea capitis. <i>Clinical and Experimental Dermatology</i> , 1998, 23, 103-108.	0.6	33
90	Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail. <i>Journal of the American Academy of Dermatology</i> , 1998, 38, S103-S109.	0.6	35
91	Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernail. <i>Journal of the American Academy of Dermatology</i> , 1998, 38, S110-S116.	0.6	24
92	Efficacy of itraconazole in children with <i>Trichophyton tonsurans</i> tinea capitis. <i>Journal of the American Academy of Dermatology</i> , 1998, 38, 443-446.	0.6	47
93	Oral antifungal agents for onychomycosis. <i>Lancet, The</i> , 1998, 351, 541-542.	6.3	34
94	Fast-track publication at <i>The Lancet</i> . <i>Lancet, The</i> , 1998, 351, 542.	6.3	4
95	Pharmacoeconomic Analysis of Oral Antifungal Therapies Used to Treat Dermatophyte Onychomycosis of the Toenails. <i>Pharmacoeconomics</i> , 1998, 13, 243-256.	1.7	30

#	ARTICLE	IF	CITATIONS
96	Clinical Pharmacology of Systemic Antifungal Agents: A Comprehensive Review of Agents in Clinical Use, Current Investigational Compounds, and Putative Targets for Antifungal Drug Development. <i>Advances in Pharmacology</i> , 1998, 44, 343-500.	1.2	333
97	Efficacy and Safety of Short-Term Itraconazole in Tinea pedis: A Double-Blind, Randomized, Placebo-Controlled Trial. <i>Dermatology</i> , 1998, 197, 368-372.	0.9	15
98	Itraconazole in the Treatment of Onychomycosis: A Double-Blind Comparison with Miconazole. <i>Dermatology</i> , 1998, 196, 323-329.	0.9	24
99	Epidemiology and in vitro activity of antimycotics against candidal vaginal/skin/nail infections in Singapore. <i>International Journal of Dermatology</i> , 1998, 37, 145-149.	0.5	14
100	Therapeutic Efficacy and Safety of One-Week Intermittent Therapy with Itraconazole for Onychomycosis in a Chinese Patient Population. <i>Dermatology</i> , 1999, 199, 47-49.	0.9	24
101	Open randomized comparison of different itraconazole regimens for the treatment of onychomycosis. <i>Journal of Dermatological Treatment</i> , 1999, 10, 245-249.	1.1	7
102	The safety of itraconazole in the diabetic population. <i>Journal of the American Podiatric Medical Association</i> , 1999, 89, 339-345.	0.2	23
103	Randomized Double-blind Comparison of Short-term Itraconazole and Terbinafine Therapy for Toenail Onychomycosis. <i>Acta Dermato-Venereologica</i> , 1999, 79, 221-223.	0.6	41
104	Drug Testing with Alternative Matrices II. Mechanisms of Cocaine and Codeine Deposition in Hair. <i>Journal of Analytical Toxicology</i> , 1999, 23, 396-408.	1.7	29
105	Continuous and intermittent itraconazole dosing schedules for the treatment of onychomycosis: a pharmacokinetic comparison. <i>British Journal of Dermatology</i> , 1999, 140, 96-101.	1.4	31
106	Pharmacokinetics of orally administered antifungals in onychomycosis. <i>International Journal of Dermatology</i> , 1999, 38, 20-27.	0.5	18
107	The use of intermittent itraconazole therapy for superficial mycotic infections: a review and update on the 'one week' approach. <i>International Journal of Dermatology</i> , 1999, 38, 28-39.	0.5	11
108	Fluconazole vs. Itraconazole in the treatment of tinea versicolor. <i>International Journal of Dermatology</i> , 1999, 38, 601-603.	0.5	23
109	Clinical and pharmacokinetic investigations of oral itraconazole in the treatment of onychomycosis. <i>Mycoses</i> , 1999, 42, 79-91.	1.8	13
110	Pathogenesis and treatment of hyperkeratotic tinea pedis in Japan. <i>Mycoses</i> , 1999, 42, 21-28.	1.8	12
111	Tinea Capitis: An Overview with Emphasis on Management. <i>Pediatric Dermatology</i> , 1999, 16, 171-189.	0.5	94
112	The new oral antifungal agents for onychomycosis of the toenails. <i>Journal of the European Academy of Dermatology and Venereology</i> , 1999, 13, 1-13.	1.3	47
113	Pharmacokinetics of fluconazole in skin and nails. <i>Journal of the American Academy of Dermatology</i> , 1999, 40, S14-S20.	0.6	27

#	ARTICLE	IF	CITATIONS
114	Oral therapy of common superficial fungal infections of the skin. <i>Journal of the American Academy of Dermatology</i> , 1999, 40, S31-S34.	0.6	64
115	Disseminated sporotrichosis with extensive cutaneous involvement in a patient with AIDS. <i>Journal of the American Academy of Dermatology</i> , 1999, 40, 350-355.	0.6	61
116	Management of Onychomycoses. <i>Drugs</i> , 1999, 58, 283-296.	4.9	66
117	Comparison of the Therapeutic Efficacy of Oral Doses of Fluconazole and Griseofulvin in a Guinea Pig Model of Dermatophytosis.. <i>Journal of Antibiotics</i> , 2000, 53, 207-210.	1.0	8
118	An evaluation of intermittent therapies used to treat onychomycosis and other dermatomycoses with the oral antifungal agents. <i>International Journal of Dermatology</i> , 2000, 39, 401-411.	0.5	37
119	Comparison of the therapeutic efficacy of oral doses of fluconazole and itraconazole in a guinea pig model of dermatophytosis. <i>Journal of Infection and Chemotherapy</i> , 2000, 6, 41-44.	0.8	14
120	Itraconazole pulse therapy is effective in dermatophyte onychomycosis of the toenail: a double-blind placebo-controlled study. <i>Journal of Dermatological Treatment</i> , 2000, 11, 33-37.	1.1	19
121	Sequential pulse therapy with itraconazole and terbinafine to treat onychomycosis of the fingernails. <i>Journal of Dermatological Treatment</i> , 2000, 11, 151-154.	1.1	12
122	Tinea capitis. <i>Medical Mycology</i> , 2000, 38, 255-287.	0.3	152
123	Itraconazole Pulse Therapy for Dermatophyte Onychomycosis in Children. <i>JAMA Pediatrics</i> , 2000, 154, 614.	3.6	44
124	Tinea capitis: A current perspective. <i>Journal of the American Academy of Dermatology</i> , 2000, 42, 1-20.	0.6	331
125	Ciclopirox nail lacquer solution 8% in the 21st century. <i>Journal of the American Academy of Dermatology</i> , 2000, 43, S96-S102.	0.6	45
126	Tinea Gladiatorum. <i>Sports Medicine</i> , 2000, 29, 439-447.	3.1	52
127	NEW AND EMERGING THERAPIES IN PEDIATRIC DERMATOLOGY. <i>Dermatologic Clinics</i> , 2000, 18, 73-78.	1.0	8
128	Itraconazole. <i>Expert Opinion on Pharmacotherapy</i> , 2000, 1, 287-304.	0.9	57
129	A Risk-Benefit Assessment of the Newer Oral Antifungal Agents Used to Treat Onychomycosis. <i>Drug Safety</i> , 2000, 22, 33-52.	1.4	76
130	Pharmacology of Itraconazole. <i>Drugs</i> , 2001, 61, 27-37.	4.9	213
131	The use of the new oral antifungal agents, itraconazole, terbinafine, and fluconazole to treat onychomycosis and other dermatomycoses. <i>Current Problems in Dermatology</i> , 2001, 13, 213-246.	0.1	14

#	ARTICLE	IF	CITATIONS
132	Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. <i>Journal of the American Academy of Dermatology</i> , 2001, 44, 485-491.	0.6	79
133	Onicomycosis en la infancia. <i>Piel</i> , 2001, 16, 511-516.	0.0	0
134	Itraconazole: an effective oral antifungal for onychomycosis. <i>International Journal of Dermatology</i> , 2001, 40, 1-5.	0.5	29
135	Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2001, 26, 159-169.	0.7	192
136	Efficacy of itraconazole as a combined continuous/pulse therapy in feline dermatophytosis: preliminary results in nine cases. <i>Veterinary Dermatology</i> , 2001, 12, 347-350.	0.4	28
137	Intermittent low dose itraconazole treatment for onychomycosis - long term follow-up. <i>Medical Mycology</i> , 2001, 39, 471-473.	0.3	11
140	Efficacy of Itraconazole in the Prophylactic Treatment of Pityriasis (Tinea) Versicolor. <i>Archives of Dermatology</i> , 2002, 138, 69-73.	1.7	44
141	Tinea Capitis. <i>Paediatric Drugs</i> , 2002, 4, 779-783.	1.3	40
142	Comparison of pulse administration versus once daily administration of itraconazole for the treatment of <i>Malassezia pachydermatis</i> dermatitis and otitis in dogs. <i>Journal of the American Veterinary Medical Association</i> , 2002, 220, 1807-1812.	0.2	36
143	Itraconazole therapy for white piedra affecting scalp hair. <i>Journal of the American Academy of Dermatology</i> , 2002, 47, 415-418.	0.6	46
144	Antifungal agents: unapproved uses, dosages, or indications. <i>Clinics in Dermatology</i> , 2002, 20, 481-489.	0.8	12
145	Efficacy and safety of itraconazole use in children. <i>Dermatologic Clinics</i> , 2003, 21, 521-535.	1.0	39
146	Itraconazole (Sporanox®) in superficial and systemic fungal infections. <i>Expert Review of Anti-Infective Therapy</i> , 2003, 1, 531-542.	2.0	19
147	The use of oral antifungal agents to treat onychomycosis. <i>Dermatologic Clinics</i> , 2003, 21, 469-479.	1.0	39
148	Itraconazole versus terbinafine in the management of onychomycosis: an overview. <i>Journal of Dermatological Treatment</i> , 2003, 14, 30-42.	1.1	8
149	Seborrheic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2004, 18, 13-26.	1.3	215
150	Treatment of head and neck dermatitis comparing itraconazole 200 mg and 400 mg daily for 1 week with placebo. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2004, 18, 445-449.	1.3	78
151	Pharmacokinetic investigation of oral itraconazole in stratum corneum level of tinea pedis. <i>Pharmakokinetische Untersuchungen zu oral appliziertem Itraconazol im Stratum corneum bei Tinea pedis. Mycoses</i> , 2004, 47, 104-114.	1.8	9

#	ARTICLE	IF	CITATIONS
152	Intracutaneous Distributions of Fluconazole, Itraconazole, and Griseofulvin in Guinea Pigs and Binding to Human Stratum Corneum. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 216-223.	1.4	40
153	Single-Dose Fluconazole versus Itraconazole in Pityriasis versicolor. <i>Dermatology</i> , 2004, 208, 55-59.	0.9	27
154	Superficial fungal infections. <i>Lancet, The</i> , 2004, 364, 1173-1182.	6.3	235
155	Structure and Function of the Nail Unit. , 2005, , 13-25.		9
156	Progress on New Therapeutics for Fungal Nail Infections. <i>Annual Reports in Medicinal Chemistry</i> , 2005, 40, 323-335.	0.5	12
157	An Overview of Antifungal Drugs and Their Use for Treatment of Deep and Superficial Mycoses in Animals. <i>Topics in Companion Animal Medicine</i> , 2005, 20, 240-249.	0.6	50
158	Pharmacokinetics and tissue distribution of itraconazole after oral and intravenous administration to horses. <i>American Journal of Veterinary Research</i> , 2005, 66, 1694-1701.	0.3	46
159	Pharmacotherapy of onychomycosis. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 609-624.	0.9	31
160	Cutaneous distribution of orally administered itraconazole in guinea pigs, studied by autoradiography. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006, 3, 475-478.	1.3	3
161	Tinea Capitis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2006, 4, 1085-1091.	0.4	28
162	Tinea Capitis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2006, 4, ---.	0.4	0
163	Determination of terbinafine in nail samples during systemic treatment for onychomycoses. <i>British Journal of Dermatology</i> , 1990, 123, 481-486.	1.4	62
164	Antifungal azoles for skin disorders. <i>Expert Opinion on Therapeutic Patents</i> , 2006, 16, 1235-1253.	2.4	13
165	Human Pharmacogenomic Variations and Their Implications for Antifungal Efficacy. <i>Clinical Microbiology Reviews</i> , 2006, 19, 763-787.	5.7	35
166	Tinea capitis: ringworm of the scalp. <i>Mycoses</i> , 2007, 50, 218-226.	1.8	43
167	Onychomycosis Treated with Itraconazole or Griseofulvin Alone with and without a Topical Antimycotic or Keratolytic Agent. <i>International Journal of Dermatology</i> , 1991, 30, 586-589.	0.5	53
168	Drug delivery strategies for improved azole antifungal action. <i>Expert Opinion on Drug Delivery</i> , 2008, 5, 1199-1216.	2.4	57
169	Itraconazole in the treatment of tinea corporis and tinea cruris: comparison of two treatment schedules: Itraconazol bei der Behandlung der Tinea corporis und Tinea cruris: Vergleich zweier Behandlungsschemata. <i>Mycoses</i> , 1998, 41, 509-514.	1.8	18

#	ARTICLE	IF	CITATIONS
170	Itraconazole in the treatment of tinea pedis and tinea manuum: comparison of two treatment schedules: Itraconazol bei der Behandlung der Tinea pedis und Tinea manuum: Vergleich zweier Behandlungsschemata. <i>Mycoses</i> , 1998, 41, 515-520.	1.8	17
171	Safety and efficacy of intermittent therapy with itraconazole in finger and toenail onychomycosis: a multicentre trial: Sicherheit und Wirksamkeit der intermittierenden Itraconazol-Therapie von Onychomykosen der Finger und Zehen. Eine Multizenter-Studie. <i>Mycoses</i> , 1998, 41, 521-527.	1.8	33
172	Skin penetration from the inside to the outside: A review. <i>Drug Discovery Today Disease Mechanisms</i> , 2008, 5, e229-e235.	0.8	11
173	Pityriasis capitis (dermatitis seborreica del cuero cabelludo): etiología y tratamiento. <i>Piel</i> , 2008, 23, 525-528.	0.0	0
174	Skin Blister Fluid Levels of Ketoconazole During Repetitive Administration in Healthy Man. <i>Mycoses</i> , 1989, 32, 39-45.	1.8	9
175	Pharmacokinetics of Topical and Oral Antifungals. <i>Mycoses</i> , 1989, 32, 34-38.	1.8	4
176	Bioavailability of fluconazole in the skin after oral medication. <i>Mycoses</i> , 1994, 37, 127-130.	1.8	85
177	The significance of itraconazole for treatment of fungal infections of skin, nails and mucous membranes. <i>JDDG - Journal of the German Society of Dermatology</i> , 2009, 7, 11-19.	0.4	23
178	Stellenwert von Itraconazol in der Behandlung von Pilzinfektionen der Haut, Nägel und Schleimhäute. <i>JDDG - Journal of the German Society of Dermatology</i> , 2009, 7, 11-20.	0.4	23
179	Itraconazole Pulse Therapy for Tinea Capitis: A Novel Treatment Schedule. <i>Pediatric Dermatology</i> , 1998, 15, 225-228.	0.5	8
180	Efficacy and safety of itraconazole pulses vs. continuous regimen in cutaneous sporotrichosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 302-305.	1.3	23
181	Treatment of tinea capitis – a critical appraisal. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, 109-114.	0.4	21
182	Die Behandlung der Tinea capitis - eine kritische Bestandsaufnahme. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, 109-115.	0.4	14
183	The Treatment of Hyperkeratotic Type Tinea Pedis and Current Problems. <i>Nihon Ika Daigaku Igakkai Zasshi</i> , 2013, 9, 6-13.	0.0	0
184	Effect of ethnicity, gender and age on the amount and composition of residual skin surface components derived from sebum, sweat and epidermal lipids. <i>Skin Research and Technology</i> , 2014, 20, 97-107.	0.8	45
185	Tissue Penetration of Antifungal Agents. <i>Clinical Microbiology Reviews</i> , 2014, 27, 68-88.	5.7	319
186	Fungal infections of the skin and nail: new treatment options. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 1389-1405.	2.0	21
187	A retrospective descriptive study of oral azole antifungal agents in patients with patch test-negative head and neck predominant atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 480-483.	0.6	43

#	ARTICLE	IF	CITATIONS
188	Mechanism for transport of ivermectin to the stratum corneum in rats. Drug Metabolism and Pharmacokinetics, 2015, 30, 385-390.	1.1	6
189	Successful treatment of oral itraconazole for infantile hemangiomas: A case series. Journal of Dermatology, 2015, 42, 202-206.	0.6	22
190	Clinical Pharmacology of Itraconazole in Children and Adolescents. Current Fungal Infection Reports, 2015, 9, 65-73.	0.9	2
191	Antibiotic and Antifungal Therapies in Dermatology. , 2016, , .		0
192	Onychomycosis. , 2016, , 203-289.		2
193	Efficacy of itraconazole oral solution using an alternating-week pulse therapy regimen for treatment of cats with experimental <i>Microsporum canis</i> infection. Journal of Feline Medicine and Surgery, 2018, 20, 869-874.	0.6	6
194	Therapy and Antifungal Susceptibility Profile of <i>Microsporum canis</i> . Journal of Fungi (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 502 T	1.5	32
195	Systemic Therapy of Onychomycosis. , 2018, , 185-214.		1
196	Structure and Function of the Nail Unit. , 2018, , 83-97.		6
197	Antifungal resistance in dermatophytes: Recent trends and therapeutic implications. Fungal Genetics and Biology, 2019, 132, 103255.	0.9	113
198	Parameters that determine dissolution and efficacy of itraconazole and its relevance to recalcitrant dermatophytoses. Expert Review of Clinical Pharmacology, 2019, 12, 443-452.	1.3	18
199	Treatment of Tinea Capitis. Skin Appendage Disorders, 2019, 5, 201-210.	0.5	29
200	S1 guidelines: Tinea capitis. JDDG - Journal of the German Society of Dermatology, 2020, 18, 161-179.	0.4	18
202	Systemic Antifungal Agents. , 2021, , 99-113.e4.		2
203	Clinical assessment of Super bioavailable Itraconazole 50 mg in dermatophytosis (Clear 50). IP Indian Journal of Clinical and Experimental Dermatology, 2021, 7, 125-129.	0.0	3
204	An Open-Label, Randomized, Double-Arm Clinical Trial to Compare the Effectiveness and Safety of Super Bioavailable Itraconazole Capsules and Itraconazole Capsules in the Management of Dermatophytosis in India. Clinical, Cosmetic and Investigational Dermatology, 2021, Volume 14, 1367-1376.	0.8	7
205	Predicting a therapeutic cutâ€off serum level of itraconazole in recalcitrant tinea corporis and crurisâ€A prospective trial. Mycoses, 2021, 64, 1480-1488.	1.8	20
206	Superficial Fungal Infection. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
207	Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Archives of Dermatology, 1996, 132, 34-41.	1.7	145
208	Skin Kinetics of Azole Antifungal Drugs. Current Topics in Medical Mycology, 1992, 4, 88-136.	0.8	14
209	The Treatment of Superficial Skin Infections Caused by Dermatophytes. Current Topics in Medical Mycology, 1992, 4, 189-206.	0.8	3
210	Pharmacokinetics of Antifungals. , 1990, , 245-254.		1
211	Short treatment schedules of itraconazole in dermatophytosis. International Journal of Dermatology, 1998, 37, 446-448.	0.5	6
212	Itraconazole: A New Triazole Antifungal Agent. Infection Control and Hospital Epidemiology, 1994, 15, 397-410.	1.0	26
213	Pharmacologic basis for the treatment of tinea capitis. Pediatric Infectious Disease Journal, 1999, 18, 191-199.	1.1	25
214	A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe nail onychomycosis. British Journal of Dermatology, 1997, 136, 230-234.	1.4	59
215	Generalized exfoliative skin rash as an early predictor of supratherapeutic voriconazole trough levels in a leukemic child: A case report. Current Medical Mycology, 2020, 6, 73-78.	0.8	1
216	Tinea Capitis. , 2002, 4, 779.		4
217	Examination of effectiveness of fluconazole oral administration on hyperkeratosis type foot ringworm and transferability to keratin.. Nishinihon Journal of Dermatology, 1996, 58, 668-675.	0.0	1
218	Clinical and pharmacokinetic examination on itraconazole internal therapy for onychomycosis.. Nishinihon Journal of Dermatology, 1996, 58, 887-895.	0.0	2
219	Is antifungal resistance a cause for treatment failure in dermatophytosis: A study focused on tinea corporis and cruris from a tertiary centre?. Indian Dermatology Online Journal, 2018, 9, 90.	0.2	39
220	Potency and Preclinical Evidence of Synergy of Oral Azole Drugs and Miltefosine in an <i>Ex Vivo</i> Model of <i>Leishmania</i> (<i>Viannia</i>) <i>panamensis</i> Infection. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0142521.	1.4	4
221	Established and Emerging Oral Antifungals in Dermatology. , 2007, , 283-296.		0
224	Methodik von klinischen Studien bei Acne vulgaris. , 1990, , 101-111.		0
225	Pilzinfektionen. , 1995, , 19-51.		0
226	Antifungal chemotherapy. , 1995, 44, 87-127.		7

#	ARTICLE	IF	CITATIONS
227	Antifungal Agents. , 0, , 2221-2235.		0
228	Adli Toksikolojik Analizlerde Alternatif Ā–rnekte TĀ±rnak. Adli TĀ±p BĀ¼lteni, 2018, 23, 47-52.	0.0	0
229	Onychomycosis. New therapies for an old disease. Western Journal of Medicine, 1996, 165, 349-51.	0.3	3
230	Onychomycosis. Going for cure. Canadian Family Physician, 1997, 43, 299-305.	0.1	9
231	Super Bioavailable Itraconazole and Its Place and Relevance in Recalcitrant Dermatophytosis: Revisiting Skin Levels of Itraconazole and Minimum Inhibitory Concentration Data. Indian Dermatology Online Journal, 2021, 12, 1-5.	0.2	0
232	Super bioavailable itraconazole and its place and relevance in recalcitrant dermatophytosis: Revisiting skin levels of itraconazole and minimum inhibitory concentration data. Indian Dermatology Online Journal, 2021, 12, 1.	0.2	12
233	Percutaneous egression: What do we know?. Skin Pharmacology and Physiology, 2022, , .	1.1	0
234	Stevens-Johnson syndrome linked to tramadol use and ultraviolet radiation. Medicine, Case Reports and Study Protocols, 2021, 2, e0176.	0.0	1
235	Systemic antifungal agents. , 2013, , 98-120.e3.		11
236	Serum and sebum pharmacokinetics evaluation of a novel formulation of itraconazole in healthy volunteers. Indian Journal of Drugs in Dermatology, 2022, 8, 7.	0.0	1
238	Effect of Different Itraconazole Dosing Regimens on Cure Rates, Treatment Duration, Safety, and Relapse Rates in Adult Patients With Tinea Corporis/Cruris. JAMA Dermatology, 2022, 158, 1269.	2.0	19
239	Comparative analysis of serum and sebum concentration of super-bioavailable itraconazole 50 versus 65 mg in healthy adult volunteers. International Journal of Research in Dermatology, 2022, 9, 59.	0.0	1
240	Pharmacokinetic and clinical comparison of super-bioavailable itraconazole and conventional itraconazole at different dosing in dermatophytosis. Drugs in Context, 0, 12, 1-11.	1.0	2
241	Pediatric tinea capitis in Jilin Province: analyzing previous results from a new perspective. Mycopathologia, 2023, 188, 515-522.	1.3	2
242	Nail Analysis in Forensic Toxicology. , 2016, , 400-410.		0
243	No evidence of resistance to itraconazole in a prospective real-world trial of dermatomycosis in India. PLoS ONE, 2023, 18, e0281514.	1.1	2